Developer docs
API playgroundTry for free, no card

Search company profiles

Sijian Bio

Full company profile

uuid000385w

Namestring
Sijian Bio
Legal namestring
Shanghai Escugen Biotechnology Co., Ltd. (上海诗健生物科技有限公司)
Websiteurl
escugen.com.cn
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Sijian Bio is a clinical-stage biotechnology company founded in 2017 and headquartered in Shanghai's Zhangjiang Hi-Tech Park, focused on developing innovative therapeutics for oncology and autoimmune diseases. The company's core asset is its proprietary EZWi-Fit® ADC linker-payload technology platform, which employs stable-cleavable cysteine linkers conjugated with Topoisomerase I inhibitor payloads (SN38/exatecan). The platform is claimed to deliver superior in vivo antitumor activity, improved safety and pharmacokinetics, activity in MMAE/Dxd-resistant models, and effective bystander killing in heterogeneous tumors, with globally owned intellectual property and freedom-to-operate space.

Sijian Bio's lead pipeline candidate ESG401, a Trop-2 ADC with DAR=8, is in two Phase III registrational trials in China for HR+/HER2- breast cancer and first-line triple-negative breast cancer (TNBC), and received CDE Breakthrough Therapy Designation in November 2024. ESMO 2025 data reported 82.9% ORR and 13.0-month median PFS in 1L mTNBC. The second clinical asset, ESG206, is a First-in-Class glycoengineered anti-BAFF-R monoclonal antibody in Phase I/II development for ITP, Sjögren's syndrome, and SLE, while ESG406 (next-generation ADC) entered Phase I in 2025. Multiple earlier-stage ADC candidates (ESG403, ESG407/DLL3, ESG409/B7-H3, ESG411/412/413 bispecifics, ESG414/416/421) round out the pipeline.

Sijian Bio operates an asset-light, partnership-driven commercialization model. The company has no commercial products; instead it monetizes the EZWi-Fit® platform and select pipeline assets through upfront fees, milestone payments, and tiered royalties on net sales. Notable transactions include a $1.03 billion global licensing of IPN60300/ESG408 to Ipsen (July 2024), an exclusive option agreement with ConjugateBio with potential milestones exceeding $100 million (April 2025), and multiple regional/global platform licenses (Anke Bio, Sidewinder, Innolake, SunRock Biopharma, Sovran Bio, Huahui Health). Cumulative disclosed equity funding is approximately CNY 305 million (~USD 42 million) across Seed, Pre-A, Series A, and Series A+ rounds.

Short descriptiontext

Sijian Bio is a Shanghai-based clinical-stage biotechnology company developing oncology and autoimmune therapeutics based on its proprietary EZWi-Fit® ADC linker-payload platform, monetized primarily through global licensing and co-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPudong, China
HQ citystring
Pudong
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, oncology drug development, ADC linker-payload platform, monoclonal antibody therapeutics, autoimmune disease biologics
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antibody-Drug Conjugates (ADC) / Oncology Biologics
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Technology Licensing
TypeLicensing Royalties
Description

Sijian Bio licenses its EZWi-Fit® ADC platform technology to domestic and international biotech companies, receiving upfront payments, milestone payments, and tiered royalties on net sales.

thepharmaletter.com
2Co-development and Licensing Deals
TypeLicensing Royalties
Description

Joint development of ADC candidates with partners, followed by out-licensing to global pharmaceutical companies for development and commercialization. Example: FS001/ESG408 licensed to Ipsen for $1.03 billion total deal value.

escugen.com.cn
3Milestone Payments
TypeLicensing Royalties
Description

Development, regulatory, and commercialization milestone payments from platform licensing and co-development partnerships, such as over $100 million from ConjugateBio and over $1 billion from Ipsen.

escugen.com.cn
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1EZWi-Fit®
Description

Next-generation ADC linker-payload technology platform with global IP, featuring stable cleavable linkers and Topoisomerase I inhibitor payloads with superior safety, efficacy, anti-drug resistance, and pharmacokinetic properties.

escugen.com.cn
+3 more records
Core offering1 text field

Sijian Bio develops a proprietary next-generation antibody-drug conjugate (ADC) linker-payload technology platform called EZWi-Fit® and uses it to build a clinical-stage pipeline of oncology and autoimmune drug candidates. The company monetizes its platform and pipeline primarily through out-licensing and co-development partnerships with domestic and international biopharmaceutical companies, receiving upfront payments, development and regulatory milestones, and tiered royalties on net sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 82.9% ORR in first-line TNBC with 13.0 months median PFS (ESMO 2025 data)
+3 more records
Product overview1 text field

Sijian Bio is a clinical-stage biotechnology company headquartered in Shanghai, China (established 2017 in Zhangjiang Hi-Tech Park), focusing on innovative drug development for oncology and autoimmune diseases. The company's proprietary EZWi-Fit® platform is a next-generation ADC linker-payload technology with global IP. The lead product ESG401 (Trop2 ADC) has entered Phase III clinical trials in China for breast cancer and received Breakthrough Therapy Designation for first-line TNBC. ESG206 (BAFF-R mAb) is advancing through clinical trials for B-cell malignancies and autoimmune diseases including ITP and Sjögren's syndrome. The company has successfully out-licensed the EZWi-Fit® platform and multiple ADC candidates (including IPN60300/FS001 to Ipsen) to international partners, and maintains a pipeline of multiple ADC candidates at various clinical and preclinical stages targeting solid tumors including DLL3, B7-H3, and bispecific formats.

Product and service6 records
1EZWi-Fit® ADC Linker-Payload Platform
CategoryTechnology Platform
Description

Next-generation antibody-drug conjugate (ADC) linker-payload technology platform employing stable-cleavable linkers with topoisomerase I inhibitor payloads (SN-38 and exatecan). Globally owned IP with strong freedom-to-operate. Licensed and used internally to generate multiple ADC candidates with superior antitumor activity, anti-drug resistance, and pharmacokinetic properties versus benchmark ADC technologies.

2ESG401 (Trop2 ADC)
CategoryADC Drug - Clinical Stage (Phase III)
Description

Best-in-Class Trop2-targeted ADC composed of a humanized Trop-2 antibody conjugated to SN-38 via a stable-cleavable linker (DAR=8). Being developed for HR+/HER2- breast cancer and first-line triple-negative breast cancer (TNBC). Granted CDE Breakthrough Therapy Designation in November 2024 for first-line TNBC and is currently in Phase III clinical trials in China.

3ESG206 (BAFF-R Monoclonal Antibody)
CategoryMonoclonal Antibody - Clinical Stage (Phase I/II)
Description

First-in-Class glycoengineered (afucosylated) humanized anti-BAFF-R monoclonal antibody that blocks BAFF/BAFF-R signaling and depletes B-cells via enhanced ADCC. Being developed for B-cell malignancies and autoimmune diseases including primary immune thrombocytopenia (ITP), primary Sjogren's syndrome, and systemic lupus erythematosus. Clinical trials ongoing in China and Australia.

4ESG406
CategoryADC Drug - Clinical Stage (Phase I)
Description

Next-generation ADC developed using the EZWi-Fit® platform showing broad-spectrum antitumor activity and significant anti-drug resistance, with demonstrated activity in PDX models unresponsive to other same-target ADCs and in primary/secondary ADC-resistant models. GLP NHP safety studies showed HNSTD of 60 mg/kg. Currently in Phase I clinical trial in China for gastrointestinal tumors, lung cancer, and other solid tumors.

5IPN60300 / FS001 / ESG408 (ITGA2 ADC)
CategoryADC Drug - Out-licensed (Phase I/II)
Description

First-in-Class ADC targeting ITGA2, co-developed with Foreseen Biotech using Sijian Bio's EZWi-Fit® platform with an exatecan payload. Licensed globally to Ipsen (France) in July 2024 for total transaction value of $1.03 billion including upfront, development milestones, and commercial royalties. Currently in Phase I/II clinical trials (NCT07213817).

6SRB123 (CCR9 ADC)
CategoryADC Drug - Preclinical
Description

First-in-Class ADC targeting C-C motif chemokine receptor 9 (CCR9), co-developed with SunRock Biopharma by combining SunRock's SRB1 antibody with Sijian Bio's EZWi-Fit® linker-payload platform. Designed for solid tumors with high CCR9 expression including pancreatic, ovarian, and lung cancer.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-08
Description

Global exclusive co-development agreement for a novel undisclosed tumor target. Combines Sijian Bio's EZWi-Fit® ADC platform with Huahui Health's tumor-specific fully human antibody development capabilities to develop a potential First-in-Class ADC candidate for multiple solid tumor indications.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-16
Description

Strategic alliance to co-develop SRB123, a First-in-Class ADC targeting CCR9 for solid tumors including pancreatic, ovarian, and lung cancer. Combines SunRock's SRB1 antibody with Sijian Bio's EZWi-Fit® platform. Joint patent filed with reciprocal licensing options.

3Sovran Bio, Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-12
Description

Strategic collaboration to leverage Sovran's broad-spectrum disease targeting capabilities with Sijian Bio's EZWi-Fit® platform technology. Jointly advancing multiple novel antibody and ADC therapeutic candidates into clinical trials, with shared development responsibilities and upside.

escugen.com.cn
4ConjugateBio
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-04-25
Description

Exclusive option agreement for EZWi-Fit® platform technology licensing. ConjugateBio, based in Princeton, New Jersey, gains exclusive option to license Sijian Bio's next-generation ADC platform for specific targets. Potential milestone payments exceed $100 million plus tiered royalties on net sales.

thepharmaletter.com
5Innola (英诺湖)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-26
Description

Global exclusive licensing agreement for Innola to use EZWi-Fit® in their ADC product development. Innola负责全球范围内的临床开发、生产和商业化,向诗健生物支付首付款、里程碑付款和分级特许权使用费。

escugen.com.cn
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-17
Description

Global exclusive licensing of EZWi-Fit® platform technology for Sidewinder to develop ADC products targeting specific undisclosed targets.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-07-11
Description

FS001/ESG408 (IPN60300) licensed to Ipsen for global development, manufacturing and commercialization. Total transaction value of $1.03 billion including upfront, development milestones, and commercial royalties. ADC co-developed with Foreseen Biotech using Sijian Bio's EZWi-Fit® platform. Currently in Phase I/II clinical trials (NCT07213817).

8Xing Tai Hao (兴泰濠制药)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-13
Description

Strategic cooperation leveraging Sijian Bio's ADC R&D capabilities and EZWi-Fit® platform advantages combined with Xing Tai Hao's expertise in functional small molecule compounds, high-potency anti-tumor drug manufacturing, cGMP management, and regulatory affairs for domestic and international ADC product development.

escugen.com.cn
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-04-18
Description

ADC platform technology licensing agreement. Sijian Bio授权安科生物使用EZWi-Fit®平台进行ADC产品开发。安科生物负责大中华地区的临床开发、商业化生产和销售,并向诗健生物支付权益付款及销售提成。诗健生物保留海外权益。

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-based clinical-stage biotech with an approved ADC (Disitamab Vedotin) and a pipeline of additional ADCs including Trop-2 candidates; directly comparable to Sijian Bio as a Chinese ADC developer with global licensing ambitions and a focus on oncology biologics.

TypeDirect peer
Description

China-based clinical-stage biotech focused on ADC and oncology biologics with multiple ADC candidates in clinical development and global out-licensing deals; closely comparable in scale, business model, and target indications to Sijian Bio's ADC pipeline.

TypeDirect peer
Description

China-based biotech developing innovative biologics including ADCs and monoclonal antibodies across oncology and autoimmune indications; comparable pipeline breadth and stage as a Chinese ADC developer targeting similar tumors.

TypeBroad incumbent
Description

Large China-based pharmaceutical group with a growing oncology biologics portfolio including ADC programs; broader than Sijian Bio but competes in the same Chinese oncology ADC development landscape and pursues similar global out-licensing strategies.

TypeBroad incumbent
Description

Major Chinese biotech with approved biologics (PD-1, etc.) and a substantial ADC pipeline; competes for the same talent, partners, and global deal flow as Sijian Bio, although with broader modality coverage and commercial infrastructure.

TypeBroad incumbent
Description

Global ADC leader with Enhertu and Dato-DXd (both TopI-payload ADCs); the closest large-pharma benchmark for EZWi-Fit's mechanism and the most direct competitive threat to ESG401 in TNBC and breast cancer.

TypeBroad incumbent
Description

Owner of Trodelvy (sacituzumab govitecan), the first approved Trop-2 ADC in TNBC; the primary head-to-head competitive incumbent that ESG401 must differentiate against to gain commercial share.

TypeBroad incumbent
Description

Global ADC leader with multiple approved ADCs (Adcetris, Padcev, Tukysa, Tivdak) and a broad clinical pipeline; relevant incumbent benchmark for ADC platform business models and partnership/royalty structures similar to those Sijian Bio is building.

9Foreseen Biotechnology
TypeDirect peer
Description

China-based ADC developer that co-developed ESG408/IPN60300 with Sijian Bio and licensed it to Ipsen; directly comparable as a fellow Chinese biotech leveraging next-generation ADC technology for global out-licensing deals.

TypeEmerging player
Description

US-based clinical-stage biotech developing next-generation ADCs and antibody-drug conjugates; comparable as an emerging ADC platform player pursuing partnership-driven business models, although smaller and at an earlier stage than Sijian Bio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sijian Bio

Antibody-Drug Conjugates (ADC) / Oncology Biologicsescugen.com.cn

Sijian Bio is a Shanghai-based clinical-stage biotechnology company developing oncology and autoimmune therapeutics based on its proprietary EZWi-Fit® ADC linker-payload platform, monetized primarily through global licensing and co-development partnerships.

What Sijian Bio does

Sijian Bio is a clinical-stage biotechnology company founded in 2017 and headquartered in Shanghai's Zhangjiang Hi-Tech Park, focused on developing innovative therapeutics for oncology and autoimmune diseases. The company's core asset is its proprietary EZWi-Fit® ADC linker-payload technology platform, which employs stable-cleavable cysteine linkers conjugated with Topoisomerase I inhibitor payloads (SN38/exatecan). The platform is claimed to deliver superior in vivo antitumor activity, improved safety and pharmacokinetics, activity in MMAE/Dxd-resistant models, and effective bystander killing in heterogeneous tumors, with globally owned intellectual property and freedom-to-operate space.

Sijian Bio's lead pipeline candidate ESG401, a Trop-2 ADC with DAR=8, is in two Phase III registrational trials in China for HR+/HER2- breast cancer and first-line triple-negative breast cancer (TNBC), and received CDE Breakthrough Therapy Designation in November 2024. ESMO 2025 data reported 82.9% ORR and 13.0-month median PFS in 1L mTNBC. The second clinical asset, ESG206, is a First-in-Class glycoengineered anti-BAFF-R monoclonal antibody in Phase I/II development for ITP, Sjögren's syndrome, and SLE, while ESG406 (next-generation ADC) entered Phase I in 2025. Multiple earlier-stage ADC candidates (ESG403, ESG407/DLL3, ESG409/B7-H3, ESG411/412/413 bispecifics, ESG414/416/421) round out the pipeline.

Sijian Bio operates an asset-light, partnership-driven commercialization model. The company has no commercial products; instead it monetizes the EZWi-Fit® platform and select pipeline assets through upfront fees, milestone payments, and tiered royalties on net sales. Notable transactions include a $1.03 billion global licensing of IPN60300/ESG408 to Ipsen (July 2024), an exclusive option agreement with ConjugateBio with potential milestones exceeding $100 million (April 2025), and multiple regional/global platform licenses (Anke Bio, Sidewinder, Innolake, SunRock Biopharma, Sovran Bio, Huahui Health). Cumulative disclosed equity funding is approximately CNY 305 million (~USD 42 million) across Seed, Pre-A, Series A, and Series A+ rounds.

Sijian Bio firmographics

Firmographics
Name
Sijian Bio
Legal name
Shanghai Escugen Biotechnology Co., Ltd. (上海诗健生物科技有限公司)
Website
https://escugen.com.cn
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Sijian Bio is a Shanghai-based clinical-stage biotechnology company developing oncology and autoimmune therapeutics based on its proprietary EZWi-Fit® ADC linker-payload platform, monetized primarily through global licensing and co-development partnerships.
Ownership category
akta.pro rank

Sijian Bio industry classification

Industry
Product category
Antibody-Drug Conjugates (ADC) / Oncology Biologics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibody-drug conjugates
  • Oncology drug development
  • ADC linker-payload platform
  • Monoclonal antibody therapeutics
  • Autoimmune disease biologics

Where Sijian Bio is headquartered

Location

Headquarters

HQ city
Pudong
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Sijian Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Technology Licensing: Sijian Bio licenses its EZWi-Fit® ADC platform technology to domestic and international biotech companies, receiving upfront payments, milestone payments, and tiered royalties on net sales.
  2. Co-development and Licensing Deals: Joint development of ADC candidates with partners, followed by out-licensing to global pharmaceutical companies for development and commercialization. Example: FS001/ESG408 licensed to Ipsen for $1.03 billion total deal value.
  3. Milestone Payments: Development, regulatory, and commercialization milestone payments from platform licensing and co-development partnerships, such as over $100 million from ConjugateBio and over $1 billion from Ipsen.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Sijian Bio product offering

Product offering

Core offering

Sijian Bio develops a proprietary next-generation antibody-drug conjugate (ADC) linker-payload technology platform called EZWi-Fit® and uses it to build a clinical-stage pipeline of oncology and autoimmune drug candidates. The company monetizes its platform and pipeline primarily through out-licensing and co-development partnerships with domestic and international biopharmaceutical companies, receiving upfront payments, development and regulatory milestones, and tiered royalties on net sales.

Product overview

Sijian Bio is a clinical-stage biotechnology company headquartered in Shanghai, China (established 2017 in Zhangjiang Hi-Tech Park), focusing on innovative drug development for oncology and autoimmune diseases. The company's proprietary EZWi-Fit® platform is a next-generation ADC linker-payload technology with global IP. The lead product ESG401 (Trop2 ADC) has entered Phase III clinical trials in China for breast cancer and received Breakthrough Therapy Designation for first-line TNBC. ESG206 (BAFF-R mAb) is advancing through clinical trials for B-cell malignancies and autoimmune diseases including ITP and Sjögren's syndrome. The company has successfully out-licensed the EZWi-Fit® platform and multiple ADC candidates (including IPN60300/FS001 to Ipsen) to international partners, and maintains a pipeline of multiple ADC candidates at various clinical and preclinical stages targeting solid tumors including DLL3, B7-H3, and bispecific formats.

Differentiator

Problem solved

Functional benefit

Brands

  • EZWi-Fit®: Next-generation ADC linker-payload technology platform with global IP, featuring stable cleavable linkers and Topoisomerase I inhibitor payloads with superior safety, efficacy, anti-drug resistance, and pharmacokinetic properties.
  • ESG401
  • ESG206
  • ESG406

Products and services

  • EZWi-Fit® ADC Linker-Payload Platform Next-generation antibody-drug conjugate (ADC) linker-payload technology platform employing stable-cleavable linkers with topoisomerase I inhibitor payloads (SN-38 and exatecan). Globally owned IP with strong freedom-to-operate. Licensed and used internally to generate multiple ADC candidates with superior antitumor activity, anti-drug resistance, and pharmacokinetic properties versus benchmark ADC technologies.
  • ESG401 (Trop2 ADC) Best-in-Class Trop2-targeted ADC composed of a humanized Trop-2 antibody conjugated to SN-38 via a stable-cleavable linker (DAR=8). Being developed for HR+/HER2- breast cancer and first-line triple-negative breast cancer (TNBC). Granted CDE Breakthrough Therapy Designation in November 2024 for first-line TNBC and is currently in Phase III clinical trials in China.
  • ESG206 (BAFF-R Monoclonal Antibody) First-in-Class glycoengineered (afucosylated) humanized anti-BAFF-R monoclonal antibody that blocks BAFF/BAFF-R signaling and depletes B-cells via enhanced ADCC. Being developed for B-cell malignancies and autoimmune diseases including primary immune thrombocytopenia (ITP), primary Sjogren's syndrome, and systemic lupus erythematosus. Clinical trials ongoing in China and Australia.
  • ESG406 Next-generation ADC developed using the EZWi-Fit® platform showing broad-spectrum antitumor activity and significant anti-drug resistance, with demonstrated activity in PDX models unresponsive to other same-target ADCs and in primary/secondary ADC-resistant models. GLP NHP safety studies showed HNSTD of 60 mg/kg. Currently in Phase I clinical trial in China for gastrointestinal tumors, lung cancer, and other solid tumors.
  • IPN60300 / FS001 / ESG408 (ITGA2 ADC) First-in-Class ADC targeting ITGA2, co-developed with Foreseen Biotech using Sijian Bio's EZWi-Fit® platform with an exatecan payload. Licensed globally to Ipsen (France) in July 2024 for total transaction value of $1.03 billion including upfront, development milestones, and commercial royalties. Currently in Phase I/II clinical trials (NCT07213817).
  • SRB123 (CCR9 ADC) First-in-Class ADC targeting C-C motif chemokine receptor 9 (CCR9), co-developed with SunRock Biopharma by combining SunRock's SRB1 antibody with Sijian Bio's EZWi-Fit® linker-payload platform. Designed for solid tumors with high CCR9 expression including pancreatic, ovarian, and lung cancer.

Quantifiable outcome

  • 82.9% ORR in first-line TNBC with 13.0 months median PFS (ESMO 2025 data)
  • +3 more outcomes

Companies that use Sijian Bio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Sijian Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Sijian Bio partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered major, core, flagship and minor.

  • Huahui Health (华辉安健)majorStrategic or Co-development Partner · 8 September 2025Global exclusive co-development agreement for a novel undisclosed tumor target. Combines Sijian Bio's EZWi-Fit® ADC platform with Huahui Health's tumor-specific fully human antibody development capabilities to develop a potential First-in-Class ADC candidate for multiple solid tumor indications.
  • SunRock BiopharmamajorStrategic or Co-development Partner · 16 June 2025Strategic alliance to co-develop SRB123, a First-in-Class ADC targeting CCR9 for solid tumors including pancreatic, ovarian, and lung cancer. Combines SunRock's SRB1 antibody with Sijian Bio's EZWi-Fit® platform. Joint patent filed with reciprocal licensing options.
  • Sovran Bio, Inc.coreStrategic or Co-development Partner · 12 June 2025Strategic collaboration to leverage Sovran's broad-spectrum disease targeting capabilities with Sijian Bio's EZWi-Fit® platform technology. Jointly advancing multiple novel antibody and ADC therapeutic candidates into clinical trials, with shared development responsibilities and upside.
  • ConjugateBiomajorTechnology or Integration · 25 April 2025Exclusive option agreement for EZWi-Fit® platform technology licensing. ConjugateBio, based in Princeton, New Jersey, gains exclusive option to license Sijian Bio's next-generation ADC platform for specific targets. Potential milestone payments exceed $100 million plus tiered royalties on net sales.
  • Innola (英诺湖)coreTechnology or Integration · 26 July 2024Global exclusive licensing agreement for Innola to use EZWi-Fit® in their ADC product development. Innola负责全球范围内的临床开发、生产和商业化,向诗健生物支付首付款、里程碑付款和分级特许权使用费。
  • Sidewinder Therapeutics, Inc.coreTechnology or Integration · 17 July 2024Global exclusive licensing of EZWi-Fit® platform technology for Sidewinder to develop ADC products targeting specific undisclosed targets.
  • Ipsen Pharma SASflagshipOEM/ Whitelabel/ Licensing Partner · 11 July 2024FS001/ESG408 (IPN60300) licensed to Ipsen for global development, manufacturing and commercialization. Total transaction value of $1.03 billion including upfront, development milestones, and commercial royalties. ADC co-developed with Foreseen Biotech using Sijian Bio's EZWi-Fit® platform. Currently in Phase I/II clinical trials (NCT07213817).
  • Xing Tai Hao (兴泰濠制药)minorStrategic or Co-development Partner · 13 May 2024Strategic cooperation leveraging Sijian Bio's ADC R&D capabilities and EZWi-Fit® platform advantages combined with Xing Tai Hao's expertise in functional small molecule compounds, high-potency anti-tumor drug manufacturing, cGMP management, and regulatory affairs for domestic and international ADC product development.
  • Anke Bio (安科生物)coreTechnology or Integration · 18 April 2024ADC platform technology licensing agreement. Sijian Bio授权安科生物使用EZWi-Fit®平台进行ADC产品开发。安科生物负责大中华地区的临床开发、商业化生产和销售,并向诗健生物支付权益付款及销售提成。诗健生物保留海外权益。

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Sijian Bio competitors and assessment

Company assessment

Direct peers

  • RemeGen Co., Ltd. China-based clinical-stage biotech with an approved ADC (Disitamab Vedotin) and a pipeline of additional ADCs including Trop-2 candidates; directly comparable to Sijian Bio as a Chinese ADC developer with global licensing ambitions and a focus on oncology biologics.
  • Lepu Biopharma: China-based clinical-stage biotech focused on ADC and oncology biologics with multiple ADC candidates in clinical development and global out-licensing deals; closely comparable in scale, business model, and target indications to Sijian Bio's ADC pipeline.
  • Mabwell (Shanghai) Bioscience Co., Ltd. China-based biotech developing innovative biologics including ADCs and monoclonal antibodies across oncology and autoimmune indications; comparable pipeline breadth and stage as a Chinese ADC developer targeting similar tumors.
  • Foreseen Biotechnology: China-based ADC developer that co-developed ESG408/IPN60300 with Sijian Bio and licensed it to Ipsen; directly comparable as a fellow Chinese biotech leveraging next-generation ADC technology for global out-licensing deals.

Broad incumbents

  • CSPC Pharmaceutical Group: Large China-based pharmaceutical group with a growing oncology biologics portfolio including ADC programs; broader than Sijian Bio but competes in the same Chinese oncology ADC development landscape and pursues similar global out-licensing strategies.
  • Innovent Biologics: Major Chinese biotech with approved biologics (PD-1, etc.) and a substantial ADC pipeline; competes for the same talent, partners, and global deal flow as Sijian Bio, although with broader modality coverage and commercial infrastructure.
  • Daiichi Sankyo: Global ADC leader with Enhertu and Dato-DXd (both TopI-payload ADCs); the closest large-pharma benchmark for EZWi-Fit's mechanism and the most direct competitive threat to ESG401 in TNBC and breast cancer.
  • Gilead Sciences (Immunomedics): Owner of Trodelvy (sacituzumab govitecan), the first approved Trop-2 ADC in TNBC; the primary head-to-head competitive incumbent that ESG401 must differentiate against to gain commercial share.
  • Pfizer (Seagen): Global ADC leader with multiple approved ADCs (Adcetris, Padcev, Tukysa, Tivdak) and a broad clinical pipeline; relevant incumbent benchmark for ADC platform business models and partnership/royalty structures similar to those Sijian Bio is building.

Emerging players

  • Pyxis Oncology: US-based clinical-stage biotech developing next-generation ADCs and antibody-drug conjugates; comparable as an emerging ADC platform player pursuing partnership-driven business models, although smaller and at an earlier stage than Sijian Bio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Sijian Bio compliance and trust

Trust signal

Compliance1 record

Sijian Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sijian Bio leadership team

Management profile

Number of profiles

Profiles2 records

Sijian Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sijian Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sijian Bio

What does Sijian Bio do?

Sijian Bio develops a proprietary next-generation antibody-drug conjugate (ADC) linker-payload technology platform called EZWi-Fit® and uses it to build a clinical-stage pipeline of oncology and autoimmune drug candidates. The company monetizes its platform and pipeline primarily through out-licensing and co-development partnerships with domestic and international biopharmaceutical companies, receiving upfront payments, development and regulatory milestones, and tiered royalties on net sales.

Is Sijian Bio a public or private company?

Sijian Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sijian Bio founded?

Sijian Bio was founded in 2017. It employs 1 to 10 people.

Where is Sijian Bio based?

Sijian Bio is headquartered in Pudong, China, in the Asia region.

How does Sijian Bio make money?

Three revenue lines are on record. Platform Technology Licensing is the primary driver. The others are co-development and Licensing Deals and milestone Payments.

Who are Sijian Bio's main competitors?

Direct peers on record are RemeGen Co., Ltd., Lepu Biopharma, Mabwell (Shanghai) Bioscience Co., Ltd. and Foreseen Biotechnology. Broad incumbents are CSPC Pharmaceutical Group, Innovent Biologics, Daiichi Sankyo, Gilead Sciences (Immunomedics) and Pfizer (Seagen). Pyxis Oncology is listed as an emerging player.

Does Sijian Bio have an API?

No public API is recorded for Sijian Bio.

What industry is Sijian Bio in?

Sijian Bio's product category is Antibody-Drug Conjugates (ADC) / Oncology Biologics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals